Clinical efficacy of anti‐amyloid antibodies in apolipoprotein E ε4 homozygotes: A Bayesian reanalysis of lecanemab and donanemab phase 3 results
Lecanemab and donanemab were clinically ineffective in ApoE ε4 homozygotes.ApoE ε4 homozygotes should not receive these treatments due to inefficacy.Future trials should adopt Bayesian analysis strategies.Bayesian analysis provides evidence for or against treatment effects.Bayesian inference provides clinically interpretable results.
Authors
- Stefan Johannes Teipel (ORCID: https://orcid.org/0000-0002-3586-3194)
- Ara Khachaturian (ORCID: https://orcid.org/0000-0003-3666-1508)
- Yi Tang
Institutions
- Capital Medical University (CN)
- German Center for Neurodegenerative Diseases (DE)
- World Water Watch (US)
Publication Details
- Journal
- Alzheimer s & Dementia Translational Research & Clinical Interventions
- Published
- 2025-04-01
- DOI
- https://doi.org/10.1002/trc2.70083
- Citations
- 2
- Primary Topic
- Alzheimer's disease research and treatments
- Type
- article
- Field-Weighted Citation Impact
- 2.33